SCHEMBL17154362

SCHEMBL17154362

CC(=O)Nc1ccc2c(Nc3ccc(N)cc3)c3ccccc3nc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.74
KDM4E B2RXH2 3/20 0.74
MAPT P10636 3/20 0.74
KMT2A Q03164 3/20 0.74
MITF O75030 1/20 0.74
LMNA P02545 1/20 0.74
POLB P06746 1/20 0.74
RAD52 P43351 1/20 0.74
RECQL P46063 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
NPSR1 Q6W5P4 1/20 0.74
L3MBTL1 Q9Y468 1/20 0.74
MEN1 O00255 2/20 0.57
NPC1 O15118 1/20 0.57
PABPC1 P11940 1/20 0.57
RAB9A P51151 1/20 0.57
TERT O14746 3/20 0.55
ATM Q13315 1/20 0.53
ALDH1A1 P00352 1/20 0.52
HDAC3 O15379 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17154400 0.86 KDM1A (1.00) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL4159315 0.84 KDM4E (0.66) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL17154394 0.83 KDM1A (0.84) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL17154374 0.82 KMT2A (0.76) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL17154450 0.81 KDM1A (1.00) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL17154455 0.80 KMT2A (0.68) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL17154375 0.79 KMT2A (0.66) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL4157750 0.78 KDM4E (0.58) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL9300852 0.77 KMT2A (0.72) KDM1AKDM4EMAPTKMT2AMITF
SCHEMBL4163695 0.77 KDM4E (0.65) KDM1AKDM4EMAPTKMT2AMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183912-B2 HDMX inhibitors and their use for cancer treatment MiRx Pharmaceuticals, LLC (US) 2019-01-22 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
WO-2015153535-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MiRx Pharmaceuticals, LLC (US) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT TP53, DDX3X, API5 KDM1A 702/4885KDM4E 809/4885MAPT 2621/4885
US-10183912-B2 HDMX inhibitors and their use for cancer treatment TP53, MDM4, MDM2 KDM1A 650/4885KDM4E 839/4885MAPT 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.